外科治療における肺がんゲノム医療の現状と今後

With the identification of novel driver genes and development of molecular-targeted drugs, advances in genomic testing and treatment strategies for non-small-cell lung cancer (NSCLC) are ongoing. Since the advent of genomic testing to detect driver gene abnormalities for patients with advanced or recurrent NSCLC being considered for drug therapy, thoracic surgeons have had few opportunities to perform genomic medicine in daily clinical practice. Due to recent technological advances, genomic testing for NSCLC has shifted from single-gene testing to multiplex companion diagnostics and comprehensive genome profile, so understanding genomic medicine is becoming increasingly important in terms of treatment optimization, prognosis prediction and prevention in the field of perioperative treatment, where thoracic surgeons are primarily involved. We herein review the current status, future prospects and issues regarding genomic medicine involving respiratory surgeons.